{"id":30395,"date":"2025-03-25T16:56:48","date_gmt":"2025-03-25T08:56:48","guid":{"rendered":"https:\/\/flcube.com\/?p=30395"},"modified":"2025-03-25T16:56:50","modified_gmt":"2025-03-25T08:56:50","slug":"united-laboratories-inks-global-licensing-deal-with-novo-nordisk-for-obesity-drug","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=30395","title":{"rendered":"United Laboratories Inks Global Licensing Deal with Novo Nordisk for Obesity Drug"},"content":{"rendered":"\n

Hong Kong-based United Laboratories International Holdings Ltd (HKG: 3933<\/a>) has entered into a licensing agreement with Denmark’s Novo Nordisk A\/S (NYSE: NVO<\/a>). The deal grants Novo Nordisk global development, manufacturing, and commercialization rights to United Laboratories’ UBT251, excluding China mainland, Hong Kong, Macau, and Taiwan, where United Laboratories retains the rights.<\/p>\n\n\n\n

Drug Profile<\/strong>
UBT251 is a triple agonist targeting the receptors for GLP-1, GIP, and glucagon. It is in early-stage clinical development for the treatment of obesity, type 2 diabetes, and other metabolic diseases.<\/p>\n\n\n\n

Financial Terms<\/strong>
Under the agreement, Novo Nordisk will provide an upfront payment of USD 200 million and potential milestone payments of up to USD 1.8 billion. Additionally, United Laboratories is entitled to receive tiered royalties based on net sales of the product.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Hong Kong-based United Laboratories International Holdings Ltd (HKG: 3933) has entered into a licensing agreement…<\/p>\n","protected":false},"author":1,"featured_media":30396,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10,11],"tags":[39,1260,148,860,86,790],"class_list":["post-30395","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","category-drug","tag-diabetes","tag-hkg-3933","tag-novo-nordisk","tag-nyse-nvo","tag-obesity","tag-united-laboratories"],"yoast_head":"\nUnited Laboratories Inks Global Licensing Deal with Novo Nordisk for Obesity Drug - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Hong Kong-based United Laboratories International Holdings Ltd (HKG: 3933) has entered into a licensing agreement with Denmark's Novo Nordisk A\/S (NYSE: NVO). The deal grants Novo Nordisk global development, manufacturing, and commercialization rights to United Laboratories' UBT251, excluding China mainland, Hong Kong, Macau, and Taiwan, where United Laboratories retains the rights.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=30395\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"United Laboratories Inks Global Licensing Deal with Novo Nordisk for Obesity Drug\" \/>\n<meta property=\"og:description\" content=\"Hong Kong-based United Laboratories International Holdings Ltd (HKG: 3933) has entered into a licensing agreement with Denmark's Novo Nordisk A\/S (NYSE: NVO). The deal grants Novo Nordisk global development, manufacturing, and commercialization rights to United Laboratories' UBT251, excluding China mainland, Hong Kong, Macau, and Taiwan, where United Laboratories retains the rights.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=30395\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-25T08:56:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-25T08:56:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2519-png.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30395#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30395\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"United Laboratories Inks Global Licensing Deal with Novo Nordisk for Obesity Drug\",\"datePublished\":\"2025-03-25T08:56:48+00:00\",\"dateModified\":\"2025-03-25T08:56:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30395\"},\"wordCount\":140,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30395#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2519-png.webp\",\"keywords\":[\"Diabetes\",\"HKG: 3933\",\"Novo Nordisk\",\"NYSE: NVO\",\"Obesity\",\"United Laboratories\"],\"articleSection\":[\"Company\",\"Deals\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=30395#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30395\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=30395\",\"name\":\"United Laboratories Inks Global Licensing Deal with Novo Nordisk for Obesity Drug - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30395#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30395#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2519-png.webp\",\"datePublished\":\"2025-03-25T08:56:48+00:00\",\"dateModified\":\"2025-03-25T08:56:50+00:00\",\"description\":\"Hong Kong-based United Laboratories International Holdings Ltd (HKG: 3933) has entered into a licensing agreement with Denmark's Novo Nordisk A\\\/S (NYSE: NVO). The deal grants Novo Nordisk global development, manufacturing, and commercialization rights to United Laboratories' UBT251, excluding China mainland, Hong Kong, Macau, and Taiwan, where United Laboratories retains the rights.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30395#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=30395\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30395#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2519-png.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2519-png.webp\",\"width\":1080,\"height\":608,\"caption\":\"United Laboratories Inks Global Licensing Deal with Novo Nordisk for Obesity Drug\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30395#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"United Laboratories Inks Global Licensing Deal with Novo Nordisk for Obesity Drug\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"United Laboratories Inks Global Licensing Deal with Novo Nordisk for Obesity Drug - Insight, China's Pharmaceutical Industry","description":"Hong Kong-based United Laboratories International Holdings Ltd (HKG: 3933) has entered into a licensing agreement with Denmark's Novo Nordisk A\/S (NYSE: NVO). The deal grants Novo Nordisk global development, manufacturing, and commercialization rights to United Laboratories' UBT251, excluding China mainland, Hong Kong, Macau, and Taiwan, where United Laboratories retains the rights.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=30395","og_locale":"en_US","og_type":"article","og_title":"United Laboratories Inks Global Licensing Deal with Novo Nordisk for Obesity Drug","og_description":"Hong Kong-based United Laboratories International Holdings Ltd (HKG: 3933) has entered into a licensing agreement with Denmark's Novo Nordisk A\/S (NYSE: NVO). The deal grants Novo Nordisk global development, manufacturing, and commercialization rights to United Laboratories' UBT251, excluding China mainland, Hong Kong, Macau, and Taiwan, where United Laboratories retains the rights.","og_url":"https:\/\/flcube.com\/?p=30395","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-03-25T08:56:48+00:00","article_modified_time":"2025-03-25T08:56:50+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2519-png.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=30395#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=30395"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"United Laboratories Inks Global Licensing Deal with Novo Nordisk for Obesity Drug","datePublished":"2025-03-25T08:56:48+00:00","dateModified":"2025-03-25T08:56:50+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=30395"},"wordCount":140,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=30395#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2519-png.webp","keywords":["Diabetes","HKG: 3933","Novo Nordisk","NYSE: NVO","Obesity","United Laboratories"],"articleSection":["Company","Deals","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=30395#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=30395","url":"https:\/\/flcube.com\/?p=30395","name":"United Laboratories Inks Global Licensing Deal with Novo Nordisk for Obesity Drug - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=30395#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=30395#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2519-png.webp","datePublished":"2025-03-25T08:56:48+00:00","dateModified":"2025-03-25T08:56:50+00:00","description":"Hong Kong-based United Laboratories International Holdings Ltd (HKG: 3933) has entered into a licensing agreement with Denmark's Novo Nordisk A\/S (NYSE: NVO). The deal grants Novo Nordisk global development, manufacturing, and commercialization rights to United Laboratories' UBT251, excluding China mainland, Hong Kong, Macau, and Taiwan, where United Laboratories retains the rights.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=30395#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=30395"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=30395#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2519-png.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2519-png.webp","width":1080,"height":608,"caption":"United Laboratories Inks Global Licensing Deal with Novo Nordisk for Obesity Drug"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=30395#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"United Laboratories Inks Global Licensing Deal with Novo Nordisk for Obesity Drug"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2519-png.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30395","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=30395"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30395\/revisions"}],"predecessor-version":[{"id":30397,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30395\/revisions\/30397"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/30396"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=30395"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=30395"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=30395"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}